167 related articles for article (PubMed ID: 21077496)
1. A comparison of pregnancy rates following fresh and frozen embryo transfer according to the use of leuprolide acetate vs ganirelix vs cetrorelix.
Check JH; Wilson C; Choe JK; Amui J; Katsoff B
Clin Exp Obstet Gynecol; 2010; 37(2):105-7. PubMed ID: 21077496
[TBL] [Abstract][Full Text] [Related]
2. Evidence that the main adverse effect of ganirelix on pregnancy and implantation rates is on the embryo rather than the endometrium.
Check JH; Cohen R; Amui J; Choe JK; Brasile D
Clin Exp Obstet Gynecol; 2011; 38(4):326-7. PubMed ID: 22268265
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization.
Posada MN; Vlahos NP; Jurema MW; Bracero NJ; Wallach EE; Garcia JE
Fertil Steril; 2003 Jul; 80(1):103-10. PubMed ID: 12849810
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
Fluker M; Grifo J; Leader A; Levy M; Meldrum D; Muasher SJ; Rinehart J; Rosenwaks Z; Scott RT; Schoolcraft W; Shapiro DB;
Fertil Steril; 2001 Jan; 75(1):38-45. PubMed ID: 11163814
[TBL] [Abstract][Full Text] [Related]
5. Effect of antagonists vs agonists on in vitro fertilization outcome.
Check ML; Check JH; Choel JK; Davies E; Kiefer D
Clin Exp Obstet Gynecol; 2004; 31(4):257-9. PubMed ID: 15672958
[TBL] [Abstract][Full Text] [Related]
6. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].
Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
8. Artificial Cycle with or without a Depot Gonadotropin-releasing Hormone Agonist for Frozen-thawed Embryo Transfer: An Assessment of Infertility Type that Is Most Suitable.
Xie D; Chen F; Xie SZ; Chen ZL; Tuo P; Zhou R; Zhang J
Curr Med Sci; 2018 Aug; 38(4):626-631. PubMed ID: 30128871
[TBL] [Abstract][Full Text] [Related]
9. Comparison of embryo implantation in Wistar rats that underwent ovarian stimulation using exogenous gonadotropins associated with cetrorelix acetate or leuprolide acetate.
Torres Mde M; Donadio N; Donadio NF; Brandão AC; Heck B
Fertil Steril; 2005 Oct; 84 Suppl 2():1235-40. PubMed ID: 16210016
[TBL] [Abstract][Full Text] [Related]
10. An oocyte donation protocol using the GnRH antagonist ganirelix acetate, does not compromise embryo quality and is associated with high pregnancy rates.
Vlahos NF; Bankowski BJ; Zacur HA; Garcia JE; Wallach EE; Zhao Y
Arch Gynecol Obstet; 2005 Jun; 272(1):1-6. PubMed ID: 15838696
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders.
DiLuigi AJ; Engmann L; Schmidt DW; Benadiva CA; Nulsen JC
Fertil Steril; 2011 Jun; 95(8):2531-3. PubMed ID: 21324455
[TBL] [Abstract][Full Text] [Related]
12. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
Atkinson P; Koch J; Ledger WL
Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
[TBL] [Abstract][Full Text] [Related]
13. Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome.
Gustofson RL; Larsen FW; Bush MR; Segars JH
Fertil Steril; 2006 Jan; 85(1):251-4. PubMed ID: 16412770
[TBL] [Abstract][Full Text] [Related]
14. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
Yıldız GA; Şükür YE; Ateş C; Aytaç R
Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
[TBL] [Abstract][Full Text] [Related]
15. Repeated doses of GnRH antagonist at midcycle in artificial frozen embryo transfer cycles may not affect pregnancy outcomes.
Palmerola KL; Hsu JY; Grossman LC; Sauer MV; Lobo RA
Gynecol Endocrinol; 2017 Apr; 33(4):301-305. PubMed ID: 28010150
[TBL] [Abstract][Full Text] [Related]
16. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
[TBL] [Abstract][Full Text] [Related]
17. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.
Gustofson RL; Segars JH; Larsen FW
Hum Reprod; 2006 Nov; 21(11):2830-7. PubMed ID: 16966348
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
[TBL] [Abstract][Full Text] [Related]
19. Frozen-thawed cleavage-stage embryo transfer cycles after previous GnRH agonist or antagonist stimulation.
Bahçeci M; Ulug U; Erden HF; Tosun S; Ciray N
Reprod Biomed Online; 2009 Jan; 18(1):67-72. PubMed ID: 19146771
[TBL] [Abstract][Full Text] [Related]
20. Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders.
Wang PT; Lee RK; Su JT; Hou JW; Lin MH; Hu YM
J Assist Reprod Genet; 2002 Jan; 19(1):1-6. PubMed ID: 11893009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
